Treatment activists at International AIDS Conference, Durban stand in solidarity with breast cancer survivors who need the lifesaving drug ‘trastuzumab’


Roche has a worldwide monopoly on the breast cancer drug ‘trastuzumab’ (marketed under the brand name Herceptin).

In South Africa women with HER2 breast cancer can’t afford the drug as it costs ½ a million Rand (approximately USD 34,000 or Rs. 23 lakhs) and the healthcare system provides it to very few women who need it due to the steep cost. Continue reading

Posted in Cancer, Protest&Campaigns, Uncategorized | Leave a comment

Letter from 56 non-profits and experts to Secretary of State John Kerry on pressure on global access to medicines initiatives

To Read:



Posted in Uncategorized | Leave a comment

AIDS activists demand treatment for all

By Anika Richards, Jamaica Observer| July 18, 2016

DURBAN, South Africa — As the world observed Nelson Mandela International Day, thousands of civil rights activists from South Africa and across the world took to the streets of Durban, South Africa, calling for treatment for all while highlighting the disconnect between political promises to end AIDS and the realities on the ground. Continue reading

Posted in HIV/Aids, Uncategorized | Leave a comment

Six Indian pharma companies get new licences to supply generic drugs

By Shreerupa Mitra-Jha, Firstpost | July 8, 2016

The UN-backed Medicines Patent Pool (MPP) announced on 7 July new generic manufacturing licensing, for antiretrovirals (ARVs) and direct acting anti-viral (DAA) for treating hepatitis C, with seven pharmaceutical companies, six of which are Indian. Continue reading

Posted in Generics, Hepatitis C, Medicine Patent Pool, Uncategorized | Leave a comment

Mega trade blocs are imperiling India’s role as pharmacy of the world

Secret negotiations are on to bring the stifling provisions of the Trans Pacific Partnership into a proposed regional trade agreement that India is part of.

Mega trade blocs are imperiling India’s role as pharmacy of the world

By Latha Jishnu, The Scroll | July 8, 2016

In a kind of pincer movement, two mega trade agreements from two ends of the world are closing in on India, forcing it to reconsider many of the policies that were formulated to protect its vulnerable economy and its even more vulnerable population. Continue reading

Posted in Generics, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

The new pharma FDI policy undermines Indian generics, which may make drugs more expensive

By relaxing brownfield pharma FDI norms, the government is making way for multinational corporations to take over ‘Make in India’ generics companies.

The new pharma FDI policy undermines Indian generics,  which may make drugs more expensive

By Leena Menghaney, The Scroll | June 28, 2016

The Union government’s decision to allow up to 74% foreign direct investment in pharmaceutical companies through the automatic route could threaten competition in the pharmaceutical sector and India’s role as a supplier of low cost, life-saving drugs across the developing world. Continue reading

Posted in FDI, Generics, HIV/Aids, Uncategorized | Leave a comment

Making RCEP work

Striking a balance between opening up trade and ‘Make in India’ is essential

Source: The Hindu BusinessLine| July 12, 2016

In a major shift of tack, India may reconsider its offer of zero tariffs in its talks with members of the China-led mega trade bloc in the making, the Regional Comprehensive Economic Partnership (RCEP). Continue reading

Posted in IPR, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment